ASCO 2022 abstract plenary - 年會預覽 （全體大會）

每年的ASCO是搞腫瘤科的最大的一個年會。近些年美國在這方麵的領先被歐洲和亞洲的醫學係統挑戰，所以ESMO也非常值得去。這樣級別的大會，信息如同風暴，令人措手不及。會場也是迷宮一般。所以下周開會之前，我先把摘要瀏覽總結一下。在社區工作需要對多種疾病的進展都有所了解。

Plenary session （全體會議): :這是會議的亮點，不能錯過。
1. Lenalidomide, bortezomib, and dexamethasone (RVd) ± autologous stem cell transplantation (ASCT) and R maintenance to progression for newly diagnosed multiple myeloma (NDMM): The phase 3 DETERMINATION trial.
By Paul Richardson

From JCO 2022: https://ascopubs.org/doi/10.1200/JCO.19.02515
RVD is an induction regimen that delivers high response rates (VGPR or better) in close to 90% of patients after transplantation, and risk-adapted maintenance can deliver unprecedented long-term outcomes. This study includes the largest cohort of patients treated with RVD reported to date with long follow-up and demonstrates the ability of 3-drug induction regimens in patients with newly diagnosed multiple myeloma to result in a substantial survival benefit.

2. Panitumumab (PAN) plus mFOLFOX6 versus bevacizumab (BEV) plus mFOLFOX6 as first-line treatment in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC): Results from the phase 3 PARADIGM trial.
By Yoshino from Japan. 這事在美國已經翻篇了，沒有很多爭議，和left colon vs. right-sided colon有關。看看日本的數據有什麽新發現。

3. Trastuzumab deruxtecan (T-DXd) versus treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Results of DESTINY-Breast04, a randomized, phase 3 study.
這絕對是重磅，我賭這個數據非常好, could be practice changing

4. Phase III assessment of topotecan and cyclophosphamide and high-dose ifosfamide in rEECur: An international randomized controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma (RR-ES).
很少看肉瘤，飄過

Ref: 
http://t.email.asco.org/r/?id=ha36fb31,718c205,36aa5da&cid=DM10518&bid=171375409&p1=%4098bdmaDhGD2AQ3W5%2FzkZ2zROg9T3TGCLNgbFYo4eFSo%3D